Skip to main content

Gastrointestinal Cancer Metastatic clinical trials at UCSF
1 in progress, 1 open to new patients

  • Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

    open to eligible people ages 20–80

    This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Expansion cohorts are open for metastatic gastrointestinal cancer and neuroendocrine tumor.

    San Francisco, California and other locations